Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease

Abstract

Antiinflammatory therapy targeting the interleukin-1β innate immunity pathway with canakinumab at a dose of 150 mg every 3 months led to a significantly lower rate of recurrent cardiovascular events than placebo, independent of lipid-level lowering. (Funded by Novartis; CANTOS ClinicalTrials.gov number, NCT01327846 .).

Association of Gout With Long‐Term Cardiovascular Outcomes Among Patients With Obstructive Coronary Artery Disease

“…Low‐grade inflammation also has a major role in the development of CVDs, and elevated levels of C‐reactive protein and interleukin‐6 have been found to be associated with increased cardiovascular risk 24. Recently, canakinumab, an anti‐inflammatory agent, was found to confer cardiovascular benefit among individuals with prior MI and elevated C‐reactive protein 25. Whether individuals with gout would derive cardiovascular benefit from this therapy remains to be seen.…”

Local Production of Soluble Urokinase Plasminogen Activator Receptor and Plasminogen Activator Inhibitor‐1 in the Coronary Circulation Is Associated With Coronary Endothelial Dysfunction in Humans

“…Taken all together, these data provide another layer of evidence demonstrating the cardinal role of inflammation in the development of endothelial dysfunction and highlighting the potential important role of new anti‐inflammatory therapy, such as canakinumab,44 in early coronary artery disease.…”

Recent novel approaches to limit oxidative stress and inflammation in diabetic complications

“…10,061 patients were enrolled into the trial with previous myocardial infarction and a high‐sensitivity C‐reactive protein (Hs‐CRP) level above 2 mg L −1 49. Subjects were divided into four groups, three of which received doses of canakinumab (50, 150 or 300 mg), while the final group received a placebo.…”